BG98902A - Imidazole derivatives and their usage as cytokine inhibitors - Google Patents

Imidazole derivatives and their usage as cytokine inhibitors

Info

Publication number
BG98902A
BG98902A BG98902A BG9890294A BG98902A BG 98902 A BG98902 A BG 98902A BG 98902 A BG98902 A BG 98902A BG 9890294 A BG9890294 A BG 9890294A BG 98902 A BG98902 A BG 98902A
Authority
BG
Bulgaria
Prior art keywords
alkyl
halo
substituted
usage
naphth
Prior art date
Application number
BG98902A
Other languages
Bulgarian (bg)
English (en)
Inventor
Jerry Adams
Timothy Gallagher
John Lee
John White
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of BG98902A publication Critical patent/BG98902A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
BG98902A 1992-01-13 1994-07-12 Imidazole derivatives and their usage as cytokine inhibitors BG98902A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81955192A 1992-01-13 1992-01-13
US86724992A 1992-04-10 1992-04-10
PCT/US1993/000674 WO1993014081A1 (en) 1992-01-13 1993-01-13 Imidazole derivatives and their use as cytokine inhibitors

Publications (1)

Publication Number Publication Date
BG98902A true BG98902A (en) 1995-06-30

Family

ID=27124382

Family Applications (1)

Application Number Title Priority Date Filing Date
BG98902A BG98902A (en) 1992-01-13 1994-07-12 Imidazole derivatives and their usage as cytokine inhibitors

Country Status (21)

Country Link
US (1) US5686455A (no)
EP (2) EP0623126B1 (no)
JP (2) JP3298641B2 (no)
CN (1) CN1083473A (no)
AT (2) ATE275556T1 (no)
AU (1) AU671271B2 (no)
BG (1) BG98902A (no)
BR (1) BR9305809A (no)
CA (4) CA2351694A1 (no)
CZ (1) CZ168894A3 (no)
DE (2) DE69333616T2 (no)
ES (2) ES2242351T3 (no)
FI (1) FI943319A (no)
HU (1) HUT69714A (no)
IL (1) IL104369A0 (no)
MX (1) MX9300141A (no)
NO (1) NO942618L (no)
NZ (1) NZ249301A (no)
OA (1) OA09963A (no)
SK (1) SK83594A3 (no)
WO (1) WO1993014081A1 (no)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2053401B1 (es) * 1992-01-13 1995-03-01 Smithkline Beecham Corp Compuestos de imidazol y procedimientos para su prepacion.
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
US5783664A (en) * 1993-09-17 1998-07-21 Smithkline Beecham Corporation Cytokine suppressive anit-inflammatory drug binding proteins
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
DE69531956T2 (de) * 1994-12-13 2004-07-29 F. Hoffmann-La Roche Ag Imidazol derivate mit proteinkinase, insbesondere egf-r tyrosinkinase, inhibierender wirkung
EP0802908A4 (en) * 1995-01-12 2001-04-11 Smithkline Beecham Corp NEW COMPOUNDS
US5700826A (en) * 1995-06-07 1997-12-23 Ontogen Corporation 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance
EP1304322A3 (en) 1995-08-22 2003-11-19 Japan Tobacco Inc. Carboxylic acid compound and use thereof
US6083949A (en) * 1995-10-06 2000-07-04 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
CZ292707B6 (cs) * 1995-10-06 2003-11-12 Merck & Co., Inc Imidazolové deriváty a farmaceutický prostředek s jejich obsahem
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
WO1997016442A1 (en) * 1995-10-31 1997-05-09 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
AP9700912A0 (en) 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
EP0900083B1 (en) * 1996-01-11 2003-08-20 Smithkline Beecham Corporation Novel substituted imidazole compounds
US6372741B1 (en) 1996-03-08 2002-04-16 Smithkline Beecham Corporation Use of CSAID™ compounds as inhibitors of angiogenesis
US6096748A (en) * 1996-03-13 2000-08-01 Smithkline Beecham Corporation Pyrimidine compounds useful in treating cytokine mediated diseases
US6235760B1 (en) 1996-03-25 2001-05-22 Smithkline Beecham Corporation Treatment for CNS injuries
EP0889888A4 (en) * 1996-03-25 2003-01-08 Smithkline Beecham Corp NEW TREATMENT OF LESIONS IN THE CENTRAL NERVOUS SYSTEM
US6294541B1 (en) 1996-06-06 2001-09-25 Euro-Celtique S.A. Purine derivatives having phosphodiesterase IV inhibition activity
ES2239357T3 (es) * 1996-06-10 2005-09-16 MERCK & CO., INC. Imidazoles sustituidos que tienen actividad inhibidora de citoquinas.
EP0956018A4 (en) 1996-08-21 2000-01-12 Smithkline Beecham Corp IMIDAZOLE COMPOUNDS, COMPOSITIONS CONTAINING THEM AND THEIR USE
US5744473A (en) * 1996-09-16 1998-04-28 Euro-Celtique, S.A. PDE IV inhibitors: "bis-compounds"
EP0948495B1 (en) 1996-11-19 2004-04-14 Amgen Inc., Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
CA2271963A1 (en) * 1996-11-20 1998-05-28 Linda L. Chang Triaryl substituted imidazoles, compositions containing such compounds and methods of use
US5880139A (en) * 1996-11-20 1999-03-09 Merck & Co., Inc. Triaryl substituted imidazoles as glucagon antagonists
CA2271941A1 (en) * 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles and methods of use
WO1998022109A1 (en) * 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles as glucagon antagonists
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
AU7138298A (en) 1997-04-24 1998-11-13 Ortho-Mcneil Corporation, Inc. Substituted imidazoles useful in the treatment of inflammatory diseases
CA2293436C (en) 1997-06-12 2010-10-26 Rhone-Poulenc Rorer Limited Imidazolyl-cyclic acetals as tnf inhibitors
WO1998056377A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
EP0994870A4 (en) 1997-06-19 2002-10-23 Smithkline Beecham NEW IMIDAZOLE COMPOUNDS SUBSTITUTED BY AN ARYLOXYREST
GB9713726D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
US6040320A (en) * 1997-06-30 2000-03-21 Ortho-Mcneil Pharmaceutical, Inc. 2-substituted imidazoles useful in the treatment of inflammatory diseases
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
JP2002509537A (ja) 1997-07-02 2002-03-26 スミスクライン・ビーチャム・コーポレイション 新規なシクロアルキル置換イミダゾール化合物
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
US5840721A (en) * 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
EP1041989A4 (en) 1997-10-08 2002-11-20 Smithkline Beecham Corp NEW SUBSTITUTED CYCLOALCENYL COMPOUNDS
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
ATE428700T1 (de) 1997-11-19 2009-05-15 Kowa Co Pyridazinderivate und diese als aktiven bestandteil enthaltende medikamente
JP2002508377A (ja) 1997-12-12 2002-03-19 ユーロ−セルティーク，エス．エイ． ３−置換アデニンの製造
US6335340B1 (en) 1997-12-19 2002-01-01 Smithkline Beecham Corporation compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses
AU759297B2 (en) * 1998-02-26 2003-04-10 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrrolobenzimidazoles for treating inflammatory diseases
CN1302296A (zh) 1998-05-22 2001-07-04 史密丝克莱恩比彻姆公司 新的2－烷基取代咪唑化合物
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
JP4588215B2 (ja) * 1998-06-24 2010-11-24 ユニバーシティー オブ ダンディー ポリペプチド、ポリヌクレオチド及びそれらの用途
AU4395399A (en) * 1998-07-02 2000-01-24 Sankyo Company Limited Five-membered heteroaryl compounds
US6599910B1 (en) 1998-08-20 2003-07-29 Smithkline Beecham Corporation Substituted triazole compounds
AU761267C (en) 1998-09-09 2007-08-09 Metabasis Therapeutics, Inc. Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
DE19842833B4 (de) * 1998-09-18 2005-04-14 Merckle Gmbh 2-Arylalkylthio-imidazole, 2-Arylalkenylthio-imidazole und 2-Arylalkinylthio-imidazole als Entzündungs-Hemmstoffe und Hemmstoffe der Cytokin-Freisetzung
JP2002528506A (ja) * 1998-11-04 2002-09-03 スミスクライン・ビーチャム・コーポレイション ピリジン−４−イルまたはピリミジン−４−イル置換ピラジン
US6319928B1 (en) 1998-11-30 2001-11-20 Euro-Celtique, S.A. Purine derivatives having phosphodiesterase IV inhibition activity
US6239279B1 (en) * 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
WO2000040243A1 (en) 1999-01-08 2000-07-13 Smithkline Beecham Corporation Novel compounds
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
CA2360934A1 (en) 1999-02-22 2000-08-31 Lin-Hua Zhang Polycyclo heterocyclic derivatives as antiinflammatory agents
JP2000247959A (ja) 1999-02-26 2000-09-12 Kowa Co ピリダジン−３−オン誘導体及びこれを含有する医薬
NZ528846A (en) * 1999-03-12 2005-05-27 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
WO2000055152A1 (en) 1999-03-12 2000-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
KR20020065341A (ko) 1999-04-02 2002-08-13 유로-셀티크 소시에떼 아노뉨 포스포디에스트라스(phosphodiesterase, PDE) Ⅳ 억제작용을 가진 푸린 유도체
AU4315100A (en) * 1999-04-28 2000-11-17 Sankyo Company Limited Preventive or inhibitory agents for hepatopathy
JP2002544272A (ja) 1999-05-14 2002-12-24 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換３−ピリジル−４−アリールピロール並びに関連した治療及び予防法
MXPA02000314A (es) * 1999-07-09 2004-06-22 Boehringer Ingelheim Pharma Proceso novedoso para la sintesis de compuestos de urea substituidos con heteroarilo.
WO2001034605A1 (en) 1999-11-10 2001-05-17 Ortho-Mcneil Pharmaceutical, Inc. SUBSTITUTED 2-ARYL-3-(HETEROARYL)-IMIDAZO[1,2-a]PYRIMIDINES, AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6759410B1 (en) * 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
AU1781601A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
WO2001038314A1 (en) 1999-11-23 2001-05-31 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
ATE305787T1 (de) 1999-11-23 2005-10-15 Smithkline Beecham Corp 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
AR029803A1 (es) * 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
GB0007405D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
WO2001074811A2 (en) * 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
US6664256B1 (en) 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
ATE297392T1 (de) 2000-10-18 2005-06-15 Ortho Mcneil Pharm Inc Substituierte imidazole, die sich für die behandlung entzündlicher krankheiten eignen
JP4524072B2 (ja) 2000-10-23 2010-08-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規化合物
CA2436739A1 (en) * 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Combination agent
EP1361225B1 (en) * 2001-01-22 2007-11-07 Sankyo Company, Limited Compounds substituted with bicyclic amino groups
DE10107683A1 (de) * 2001-02-19 2002-08-29 Merckle Gmbh Chem Pharm Fabrik 2-Thio-substituierte Imidazolderivate und ihre Verwendung in der Pharmazie
US6790846B2 (en) * 2001-05-24 2004-09-14 The Procter & Gamble Company Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity
DE122010000047I1 (de) 2001-06-26 2011-05-05 Amgen Fremont Inc Antikörper gegen opgl
CA2465759A1 (en) * 2001-12-11 2003-06-19 Boehringer Ingelheim Pharmaceuticals, Inc. Method for administering birb 796 bs
EP1480973B1 (en) * 2002-02-25 2008-02-13 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
WO2003080179A1 (fr) 2002-03-27 2003-10-02 Nippon Sigmax Co., Ltd. Dispositif de regulation de cytokines, dispositif de traitement et procede de traitement
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
JP2005538066A (ja) 2002-07-09 2005-12-15 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規な抗コリン作用薬及びｐ３８キナーゼ阻害剤を用いた新規な医薬組成物
AU2003256297A1 (en) * 2002-08-09 2004-02-25 Eli Lilly And Company Benzimidazoles and benzothiazoles as inhibitors of map kinase
EP1531674B1 (en) 2002-08-19 2014-06-18 Lorus Therapeutics Inc. 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents
DE10238045A1 (de) 2002-08-20 2004-03-04 Merckle Gmbh Chem.-Pharm. Fabrik 2-Thio-substituierte Imidazolderivate und ihre Verwendung in der Pharmazie
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
MXPA05007019A (es) 2002-12-30 2005-08-18 Amgen Inc Terapia de combinacion con factores co-estimuladores.
WO2004063192A1 (en) * 2003-01-10 2004-07-29 Pharmacopeia Drug Discovery, Inc. Imidazolyl pyrimidine derivatives useful as il-8 receptor modulators
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
AU2004221966A1 (en) 2003-03-18 2004-09-30 Kowa Co., Ltd. Water-soluble phenylpyridazine derivative and medicine containing the same
CA2545942C (en) 2003-11-14 2012-07-10 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
BRPI0417543A (pt) * 2003-12-12 2007-03-27 Wyeth Corp quinolinas úteis no tratamento de doença cardiovascular
EP1703908A4 (en) * 2003-12-22 2009-07-08 Amgen Inc ARYLSULFONAMIDE COMPOUNDS AND RELATED APPLICATIONS
TWI332003B (en) * 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
JP2008520744A (ja) 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 抗炎症性ピラゾロピリミジン
US20080119498A1 (en) * 2004-12-06 2008-05-22 Masatomo Kato Therapeutic Agent for Pruritus Comprising P38 Map Kinase Inhibitor as the Active Ingredient
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
ATE538118T1 (de) 2004-12-28 2012-01-15 Aska Pharm Co Ltd Pyrimidinylisoxazolderivat
KR101327323B1 (ko) * 2005-01-14 2013-11-11 에스케이바이오팜 주식회사 옥사졸 하이드록삼산 유도체 및 이들의 용도
AR053346A1 (es) * 2005-03-25 2007-05-02 Glaxo Group Ltd Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38
EP1915374B1 (en) 2005-05-25 2014-04-02 Lorus Therapeutics Inc. 2-indolyl imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
TW200804288A (en) * 2005-12-12 2008-01-16 Astrazeneca Ab Alkylsulphonamide quinolines
KR20150038395A (ko) 2006-04-04 2015-04-08 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
JPWO2008001929A1 (ja) * 2006-06-28 2009-12-03 あすか製薬株式会社 炎症性腸疾患の処置剤
US8207203B2 (en) 2006-06-28 2012-06-26 Aska Pharmaceutical Co., Ltd. Pyridylisoxazole derivatives
AU2008215659B2 (en) 2007-02-16 2012-11-01 Aska Pharmaceutical Co., Ltd. Pharmaceutical composition comprising microparticle oily suspension
WO2008133192A1 (ja) * 2007-04-19 2008-11-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
AU2009204483B2 (en) * 2008-01-04 2014-03-13 Intellikine, Llc Certain chemical entities, compositions and methods
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
JP5819195B2 (ja) 2008-10-16 2015-11-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 融合環ヘテロアリールキナーゼ阻害剤
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
US8691866B2 (en) 2008-12-10 2014-04-08 The General Hospital Corporation HIF inhibitors and use thereof
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
CN102574781B (zh) 2009-09-30 2014-02-19 东丽株式会社 2，3-二氢-1h-茚-2-基脲衍生物及其药物用途
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
SG10201600179RA (en) 2011-01-10 2016-02-26 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
EP2678018A4 (en) 2011-02-23 2015-09-30 Intellikine Llc COMBINATION OF CHINESE HEMMER AND USES THEREOF
EP2714026A2 (en) * 2011-06-01 2014-04-09 Stichting Het Nederlands Kanker Instituut Modulation of the ubiquitin-proteasome system (ups)
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2012284091B2 (en) 2011-07-19 2015-11-12 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CA2846431A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
US20130165464A1 (en) * 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP2799537B1 (en) 2011-12-28 2021-09-22 Kyoto Prefectural Public University Corporation Normalization of culture of corneal endothelial cells
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
KR20150061651A (ko) 2012-09-26 2015-06-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ire1의 조절
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
KR20160042811A (ko) 2013-03-20 2016-04-20 압토스 바이오사이언시스 인코포레이티드 2-치환 이미다조[4,5-d]페난쓰롤린 유도체 및 암 치료에 있어서의 이의 용도
BR112015026519A2 (pt) 2013-04-19 2017-07-25 Astrazeneca Ab composto antagonista do receptor nk3 (nk3ra) para uso em um método destinado ao tratamento de síndrome do ovário policístico (sop)
MY175778A (en) 2013-10-04 2020-07-08 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
WO2015051302A1 (en) 2013-10-04 2015-04-09 Aptose Biosciences Inc. Compositions and methods for treating cancers
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10813920B2 (en) 2013-11-14 2020-10-27 The Doshisha Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage
SG11201607705XA (en) 2014-03-19 2016-10-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6980534B2 (ja) 2015-06-25 2021-12-15 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大、富化、および維持に関する方法および組成物
KR20180058741A (ko) 2015-09-14 2018-06-01 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법
DK3429603T3 (da) 2016-03-15 2022-03-14 Childrens Medical Center Fremgangsmåder og sammensætninger vedrørende ekspansion af hæmatopoietiske stamceller
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2018016227A (es) 2016-06-24 2019-07-08 Infinity Pharmaceuticals Inc Terapias de combinacion.
FR3060987B1 (fr) * 2016-12-22 2020-10-02 Oreal Procede de coloration des fibres keratiniques mettant en oeuvre au moins un colorant triarylmethane particulier et au moins un colorant fluorescent
TW201936190A (zh) 2017-10-30 2019-09-16 加拿大商艾普托斯生物科學公司 用於治療癌症之芳基咪唑

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) * 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3940486A (en) * 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
CH561716A5 (no) * 1971-05-10 1975-05-15 Ciba Geigy Ag
US3929807A (en) * 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US4005614A (en) * 1975-11-13 1977-02-01 Samuel Moore And Company Motion transfer system
US4175127A (en) * 1978-09-27 1979-11-20 Smithkline Corporation Pyridyl substituted 2,3-dihydroimidazo[2,1-b]thiazoles
CA1175431A (en) * 1980-07-25 1984-10-02 Alfred Sallmann Tri-substituted imidazole derivatives, processes for their manufacture, pharmaceutical preparations containing them, and their use
US4503065A (en) * 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
US4565875A (en) * 1984-06-27 1986-01-21 Fmc Corporation Imidazole plant growth regulators
US4686231A (en) * 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
IL83467A0 (en) * 1986-08-15 1988-01-31 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
AU3592493A (en) * 1992-01-13 1993-08-03 Smithkline Beecham Corporation Pyridyl substituted imidazoles

Also Published As

Publication number Publication date
ATE275556T1 (de) 2004-09-15
MX9300141A (es) 1994-07-29
JP2002097189A (ja) 2002-04-02
CA2368862A1 (en) 1993-07-22
NZ249301A (en) 1996-06-25
NO942618L (no) 1994-08-30
DE69333805D1 (de) 2005-06-09
CN1083473A (zh) 1994-03-09
EP0623126B1 (en) 2004-09-08
WO1993014081A1 (en) 1993-07-22
IL104369A0 (en) 1993-05-13
SK83594A3 (en) 1995-03-08
ES2242351T3 (es) 2005-11-01
DE69333616T2 (de) 2005-09-08
BR9305809A (pt) 1997-02-18
FI943319A0 (fi) 1994-07-12
ES2227517T3 (es) 2005-04-01
ATE294795T1 (de) 2005-05-15
DE69333805T2 (de) 2006-01-19
US5686455A (en) 1997-11-11
HU9402092D0 (en) 1994-09-28
HUT69714A (en) 1995-09-28
FI943319A (fi) 1994-09-12
AU3592393A (en) 1993-08-03
CA2127876C (en) 2003-05-13
CA2351694A1 (en) 1993-07-22
EP0943616B1 (en) 2005-05-04
CA2127876A1 (en) 1993-07-22
CA2314425A1 (en) 1993-07-22
NO942618D0 (no) 1994-07-12
EP0623126A1 (en) 1994-11-09
JP3298641B2 (ja) 2002-07-02
DE69333616D1 (de) 2004-10-14
OA09963A (en) 1995-12-11
AU671271B2 (en) 1996-08-22
EP0943616A1 (en) 1999-09-22
CZ168894A3 (en) 1995-01-18
JPH07503017A (ja) 1995-03-30

Similar Documents

Publication Publication Date Title
BG98902A (en) Imidazole derivatives and their usage as cytokine inhibitors
HUP0002050A2 (hu) Szubsztituált imidazolvegyületek, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
NZ324007A (en) Quinazoline derivatives susbtituted by a phenyl and medicaments
NZ330118A (en) Thiophenopyrimidines, pharmaceutical compositions thereof and use in treating endocrine, psychiatric and neurologic conditions
CA2282890A1 (en) Therapeutic heterocyclic compounds
HUP0204410A2 (en) Pyrimidine-4-one derivatives, process for their preparation, pharmaceutical compositions containing them and their use
TW200503692A (en) Therapeutic agents
MY129970A (en) Hypolipidaemic compounds
EP0564739A3 (no)
HUP0303415A2 (hu) Triazolopiridinek, mint gyulladásgátló anyagok és ezeket tartalmazó gyógyszerkészítmények
AP9901578A0 (en) Sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
MY131387A (en) Novel 4-benzoylisoxazole derivatives, compositions containing them, processes for their preparation, intermediates in their and their use as herbicides
ATE84035T1 (de) Antivirale tetrahydroimidazo(1,4)benzodiazepin-2- one.
ZA912618B (en) 3-aminochroman derivatives,process for preparing these and pharmaceutical compositions containing them
DE60216610D1 (de) Verwendung von kondensierten Pyrazolverbindungen für die Herstellung eines Arzneimittels zur Behandlung von Bluthochdruck
ZA984114B (en) Substituted heterocyclic compounds a process for the preparation thereof and pharmaceutical compositions containing them
ZA879301B (en) 2-methylthiomethyl-dihydropyridines,a process for their preparation and pharmaceutical compositions containing them
DE69808326D1 (de) Azetidinonderivate zur behandlung von hcmv entzündungen
GR3018329T3 (en) Novel benzopyran derivatives and processes for the preparation thereof.
ES473775A1 (es) Perfeccionamientos en o relacionados con compuestos organi- cos
NZ336876A (en) Process for preparation of 4-H-4-oxo-quinolizine-3-carboxylic acid derivatives
DE59309898D1 (de) 4-oxo-azetidin-2-sulfonsäureamide und ihre salze, verfahren zu deren herstellung und ihre verwendung